Syntimmune progress triggers $10M from Apple Tree, Baxalta

Syntimmune Inc., a company developing a portfolio of treatments for immunoglobulin G-mediated autoimmune diseases based on neonatal Fc receptor (FcRn) biology, has triggered a $10 million tranche of the company's committed $26 million series A financing.